CSIMarket
 


Vir Biotechnology Inc   (VIR)
Other Ticker:  
 
 

VIR's Revenue Growth by Quarter and Year

Vir Biotechnology Inc 's Revenue results by quarter and year




VIR Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 812.76 1.73 -1.40
III Quarter September 374.56 103.62 1.93 1.40
II Quarter June -40.63 177.07 66.99 0.00
I Quarter March 1,232.46 1.98 5.72 0.00
FY   1,566.39 1,095.43 76.37 0.00



VIR Revenue third quarter 2022 Y/Y Growth Comment
Vir Biotechnology Inc achieved in the third quarter 2022, above Company average Revenue surge of 261.47% year on year, to $ 374.56 millions.

Looking into third quarter 2022 results within Biotechnology & Pharmaceuticals industry 15 other companies have achieved higher Revenue growth. While Vir Biotechnology Inc ' s Revenue doubling of 261.47% ranks overall at the positon no. 210 in the third quarter 2022.




VIR Revenue ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - 46880.35 % - -
III Quarter September 261.47 % 5268.91 % 37.86 % -
II Quarter June - 164.32 % - -
I Quarter March 62145.45 % -65.38 % - -
FY   - 1334.37 % - -

Financial Statements
Vir Biotechnology Inc 's third quarter 2022 Revenue $ 374.56 millions VIR's Income Statement
Vir Biotechnology Inc 's third quarter 2021 Revenue $ 103.62 millions Quarterly VIR's Income Statement
New: More VIR's historic Revenue Growth >>


VIR Revenue (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - 684.37 % -10.36 % -
III Quarter September - -41.48 % -97.12 % -
II Quarter June - 8842.93 % 1071.15 % -
I Quarter March 51.64 % 14.45 % - -
FY (Year on Year)   - 1334.37 % - -




Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #16
Healthcare Sector #50
Overall #210

Revenue Y/Y Growth Statistics
High Average Low
285.18 % 67.59 % -9.36 %
(Dec 31 2021)   (Jun 30 2022)
Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #16
Healthcare Sector #50
Overall #210
Revenue Y/Y Growth Statistics
High Average Low
285.18 % 67.59 % -9.36 %
(Dec 31 2021)   (Jun 30 2022)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Vir Biotechnology Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
8860.93 % 1316.72 % -97.12 %
(Jun 30 2021)  


VIR's III. Quarter Q/Q Revenue Comment
This reversal of fortune III. Quarter 2022where Vir Biotechnology Inc delivered Revenue of $ 374.56 millions could be beginning of improved performance.Vir Biotechnology Inc announced in the III. Quarter 2022 Revenue of $ 374.56 millions compare to recorded in previos quarter.

Within Biotechnology & Pharmaceuticals industry Vir Biotechnology Inc achieved highest sequential Revenue growth. While Vir Biotechnology Inc 's Revenue growth quarter on quarter, overall rank is 0.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #0
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #0
Revenue Q/Q Growth Statistics
High Average Low
8860.93 % 1316.72 % -97.12 %
(Jun 30 2021)  


VIR's III. Quarter Q/Q Revenue Comment
Improvement III. Quarter 2022where Vir Biotechnology Inc delivered Revenue of $ 374.56 millions should be considered as a beginning of better results.Vir Biotechnology Inc announced in the III. Quarter 2022 Revenue of $ 374.56 millions compare to recorded in previos quarter.

Within Biotechnology & Pharmaceuticals industry Vir Biotechnology Inc achieved highest sequential Revenue growth. While Vir Biotechnology Inc 's Revenue growth quarter on quarter, overall rank is 0.


Vir Biotechnology Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
Cumulative Revenue 12 Months Ending $ 2,379.14 $ 2,108.20 $ 2,325.90 $ 1,095.42 $ 284.39
Y / Y Revenue Growth (TTM) 736.57 % 1053.88 % 3102.57 % 1334.39 % 288.35 %
Year on Year Revenue Growth Overall Ranking # 25 # 23 # 17 # 33 # 122
Seqeuential Revenue Change (TTM) 12.85 % -9.36 % 112.33 % 285.18 % 55.66 %
Seq. Revenue Growth (TTM) Overall Ranking # 490 # 2815 # 14 # 34 # 104




Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2022 period, Vir Biotechnology Inc 's cumulative twelve months Revenue were $ 2,379 millions, company would post below average annual Revenue growth of 55.66% year on year, if the fiscal year would end at Sep 30 2022.
A slow-down in the Vir Biotechnology Inc 's Revenue growth from the -40.63% growth in Jun 30 2022.

Among companies within the Healthcare sector 5 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 23 to 25.

Revenue TTM Q/Q Growth Statistics
High Average Low
285.18 %
67.59 %
-9.36 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 28
Healthcare Sector # 6
Overall # 25

Revenue TTM Y/Y Growth Statistics
High Average Low
3102.57 %
1111.17 %
151.29 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 28
Sector # 114
S&P 500 # 490
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2022 period, Vir Biotechnology Inc 's cumulative twelve months Revenue were $ 2,379 millions, company would post below average annual Revenue growth of 151.29% year on year, if the fiscal year would end at Sep 30 2022.
A slow-down in the Vir Biotechnology Inc 's Revenue growth from the -40.63% growth in Jun 30 2022.

Among companies within the Healthcare sector 5 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 23 to 25.

Revenue TTM Q/Q Growth Statistics
High Average Low
285.18 %
67.59 %
-9.36 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 28
Healthcare Sector # 6
Overall # 25

Revenue TTM Y/Y Growth Statistics
High Average Low
3102.57 %
1111.17 %
151.29 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 28
Sector # 114
S&P 500 # 490




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
VIR's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for VIR's Competitors
Revenue Growth for Vir Biotechnology Inc 's Suppliers
Revenue Growth for VIR's Customers

You may also want to know
VIR's Annual Growth Rates VIR's Profitability Ratios VIR's Asset Turnover Ratio VIR's Dividend Growth
VIR's Roe VIR's Valuation Ratios VIR's Financial Strength Ratios VIR's Dividend Payout Ratio
VIR's Roa VIR's Inventory Turnover Ratio VIR's Growth Rates VIR's Dividend Comparisons



Companies with similar Revenue doubling for the quarter ending Sep 30 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2022
Durect Corp453.21%$ 453.210 millions
Creative Medical Technology Holdings Inc 450.00%$ 450.000 millions
Arcturus Therapeutics Holdings Inc 448.58%$ 448.584 millions
Palatin Technologies Inc 445.30%$ 445.299 millions
Recursion Pharmaceuticals Inc 419.34%$ 419.337 millions
Inotiv inc 400.27%$ 400.269 millions
Jaguar Health inc 400.00%$ 400.000 millions
G1 Therapeutics Inc 385.30%$ 385.303 millions
Orchard Therapeutics Plc384.65%$ 384.648 millions
Ainos Inc 384.17%$ 384.166 millions
Transmedics Group Inc 378.27%$ 378.268 millions
Rvl Pharmaceuticals Plc356.38%$ 356.375 millions
One World Products Inc 325.40%$ 325.405 millions
Ardelyx inc 325.06%$ 325.064 millions
Rhythm Pharmaceuticals inc 316.73%$ 316.732 millions
Eton Pharmaceuticals Inc 315.35%$ 315.355 millions
Novavax inc 310.74%$ 310.736 millions
Apellis Pharmaceuticals Inc 290.37%$ 290.372 millions
Aurinia Pharmaceuticals Inc 280.30%$ 280.303 millions
Sera Prognostics Inc 278.26%$ 278.261 millions
Mirum Pharmaceuticals Inc 275.60%$ 275.600 millions
Evofem Biosciences Inc 272.14%$ 272.138 millions
Fresh Tracks Therapeutics Inc 268.18%$ 268.182 millions
Vir Biotechnology Inc 261.49%$ 261.486 millions
India Globalization Capital Inc 260.71%$ 260.714 millions
Arcus Biosciences Inc 254.94%$ 254.941 millions
Ideaya Biosciences Inc 230.87%$ 230.871 millions
Arvinas Inc 226.34%$ 226.340 millions
Intra cellular Therapies Inc 223.63%$ 223.634 millions
Orbital Infrastructure Group Inc 222.85%$ 222.850 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

SLB's Profile

Stock Price

SLB's Financials

Business Description

Fundamentals

Charts & Quotes

SLB's News

Suppliers

SLB's Competitors

Customers & Markets

Economic Indicators

SLB's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071